Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CNTY-101 |
Synonyms | |
Therapy Description |
CNTY-101 are iPSC-derived CAR-NK cells that have been engineered to express IL-15 and a chimeric antigen receptor (CAR) targeting CD19, which potentially results in tumor cell killing and inhibition of tumor growth (Blood (2021) 138 (Supplement 1): 1729). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CNTY-101 | CNTY 101|CNTY101 | CD19 Immune Cell Therapy 62 | CNTY-101 are iPSC-derived CAR-NK cells that have been engineered to express IL-15 and a chimeric antigen receptor (CAR) targeting CD19, which potentially results in tumor cell killing and inhibition of tumor growth (Blood (2021) 138 (Supplement 1): 1729). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05336409 | Phase I | CNTY-101 | A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (ELiPSE-1) | Recruiting | USA | 0 |